These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18781901)

  • 1. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
    Chisari G
    Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycopeptide tolerance in bacteria causing endocarditis.
    Perry JD; Jones AL; Gould FK
    J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin.
    Greenwood D; Bidgood K; Turner M
    J Antimicrob Chemother; 1987 Aug; 20(2):155-64. PubMed ID: 2959642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D; Brown DF; Soussy CJ
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiological properties of teicoplanin.
    Greenwood D
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():1-13. PubMed ID: 2965119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.
    Biavasco F; Lupidi R; Varaldo PE
    Antimicrob Agents Chemother; 1992 Feb; 36(2):331-8. PubMed ID: 1534977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
    Cormican MG; Erwin ME; Jones RN
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):241-8. PubMed ID: 9458981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
    Kenny MT; Dulworth JK; Brackman MA
    Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of the new glycopeptide decaplanin.
    Neu HC; Chin NX; Niu WW
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The invitro activity of teicoplanin and vancomycin against gram positive microorganisms (corrected)].
    Kayaokay Y; Hasçelik G; Gür D; Akalin E
    Mikrobiyol Bul; 1991 Oct; 25(4):321-5. PubMed ID: 1839050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
    Grüneberg RN; Hryniewicz W
    Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
    Johnson AP; Uttley AH; Woodford N; George RC
    Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.